Elsevier

Annals of Medicine and Surgery

Volume 56, August 2020, Pages 125-127
Annals of Medicine and Surgery

Case Series
Severe refractory COVID-19 patients responding to convalescent plasma; A case series

https://doi.org/10.1016/j.amsu.2020.06.018Get rights and content
Under a Creative Commons license
open access

Highlights

  • Currently, no specific antiviral drug has been approved to target novel coronavirus.

  • Convalescent plasma is a classical immunotherapy.

  • It has been used in the management of several infectious diseases for many decades.

  • In this report two severe cases of COVID-2019 have been described receiving CP.

Abstract

Introduction

Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP).

Case report

Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests.

Conclusion

CP might be an effective therapy for severe COVID-19 patients.

Keywords

COVID-19
SARS-CoV-2
Coronavirus
Convalescent plasma

Cited by (0)